DelveInsight’s, “Peripheral Arterial Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Peripheral Arterial Disease Understanding
    Peripheral Arterial Disease: Overview
    Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking. Possible symptoms include: Hair loss on the feet and legs, Numbness in the legs, A foot or the lower leg may feel cold, and leg weakness. Symptoms and medical history are being questioned by the doctor for the appropriate diagnossi of peripheral arterial disease. PAD is usually treated by aggressively managing the risk factors with lifestyle changes and medication. This includes quitting smoking, controlling blood pressure and cholesterol, controlling diabetes, and losing weight. Surgery, medications and angioplasty are some other treatment options for peripheral arterial disease.

    "Peripheral Arterial Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease.

    Peripheral Arterial Disease Emerging Drugs Chapters
    This segment of the Peripheral Arterial Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
    Peripheral Arterial Disease Emerging Drugs
    • Rivaroxaban: Janssen Pharmaceutical
    Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). A supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto; Janssen) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD) has been submitted to the Food and Drug Administration (FDA).
    • Semaglutide: Novo Nordisk
    Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently in Phase III stage of development for the treatment of patients with Type 2Diabetes Mellitus, and Peripheral Arterial Disease.
    Further product details are provided in the report??..

    Peripheral Arterial Disease: Therapeutic Assessment
    This segment of the report provides insights about the different Peripheral Arterial Disease drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Peripheral Arterial Disease
    There are approx. 20+ key companies which are developing the therapies for Peripheral Arterial Disease. The companies which have their Peripheral Arterial Disease drug candidates in the most advanced stage, i.e. Preregistration include, Janssen Pharmaceutical.
    • Phases
    DelveInsight’s report covers around 20+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • Intravenous
    • Subcutaneous
    • Topical
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Peripheral Arterial Disease: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease drugs.

    Peripheral Arterial Disease Report Insights
    • Peripheral Arterial Disease Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Peripheral Arterial Disease Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Peripheral Arterial Disease drugs?
    • How many Peripheral Arterial Disease drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Peripheral Arterial Disease and their status?
    • What are the key designations that have been granted to the emerging drugs?